Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCapital LeasesCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesLiabilities and Shareholders EquityNon-Current AssetsOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rocket Pharmaceuticals (RCKT) Non-Current Deffered Revenue (2017 - 2018)

Rocket Pharmaceuticals' Non-Current Deffered Revenue history spans 1 years, with the latest figure at $457000.0 for Q4 2018.

  • For Q4 2018, Non-Current Deffered Revenue changed N/A year-over-year to $457000.0; the TTM value through Dec 2018 reached $457000.0, changed N/A, while the annual FY2018 figure was $457000.0, N/A changed from the prior year.
  • Non-Current Deffered Revenue for Q4 2018 was $457000.0 at Rocket Pharmaceuticals, up from $438000.0 in the prior quarter.
  • Across five years, Non-Current Deffered Revenue topped out at $598000.0 in Q1 2018 and bottomed at $438000.0 in Q3 2018.